Symbols / PDSB Stock $1.30 +4.00% PDS Biotechnology Corporation

Healthcare • Biotechnology • United States • NCM
PDSB (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Frank K. Bedu-Addo Ph.D.
Exch · Country NCM · United States
Market Cap 72.56M
Enterprise Value 59.98M
Income -34.50M
Sales —
FCF (ttm) -15.72M
Book/sh -4.02
Cash/sh 0.48
Employees —
Insider 10d —
IPO Sep 30, 2015
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.42
PEG —
P/S —
P/B -0.32
P/C —
EV/EBITDA -1.91
EV/Sales —
Quick Ratio 2.82
Current Ratio 2.98
Debt/Eq 182.94
LT Debt/Eq —
EPS (ttm) -0.74
EPS next Y -0.54
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-13
Earnings (prior) 2026-03-30
ROA -51.98%
ROE -244.16%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 55.82M
Shs Float 51.57M
Insider Own 1.51%
Instit Own 13.76%
Short Float 3.18%
Short Ratio 1.70
Short Interest 1.72M
52W High 1.92
vs 52W High -32.11%
52W Low 0.51
vs 52W Low 156.41%
Beta 1.50
Impl. Vol. 20.66%
Rel Volume 1.43
Avg Volume 728.80K
Volume 1.04M
Target (mean) $7.50
Tgt Median $4.50
Tgt Low $3.00
Tgt High $15.00
# Analysts 3
Recom None
Prev Close $1.25
Price $1.30
Change 4.00%
About

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, Georgia Research Foundation, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$7.50
Mean price target
2. Current target
$1.30
Latest analyst target
3. DCF / Fair value
$-5.07
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.30
Low
$3.00
High
$15.00
Mean
$7.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-15 reit HC Wainwright & Co. Buy → Buy $15
2025-11-25 main B. Riley Securities Buy → Buy $3
2025-11-13 main HC Wainwright & Co. Buy → Buy $15
2025-07-01 reit HC Wainwright & Co. Buy → Buy $13
2025-06-11 reit HC Wainwright & Co. Buy → Buy $13
2025-03-27 main HC Wainwright & Co. Buy → Buy $13
2025-03-13 reit HC Wainwright & Co. Buy → Buy $21
2025-03-07 reit HC Wainwright & Co. Buy → Buy $21
2025-02-24 reit HC Wainwright & Co. Buy → Buy $21
2024-12-18 reit HC Wainwright & Co. Buy → Buy $21
2024-11-25 main B. Riley Securities Buy → Buy $7
2024-11-15 reit HC Wainwright & Co. Buy → Buy $21
2024-10-24 reit HC Wainwright & Co. Buy → Buy $21
2024-10-02 reit HC Wainwright & Co. Buy → Buy $21
2024-09-17 reit HC Wainwright & Co. Buy → Buy $21
2024-08-20 main Alliance Global Partners Buy → Buy $7
2024-08-01 reit HC Wainwright & Co. Buy → Buy $21
2024-06-12 reit HC Wainwright & Co. Buy → Buy $21
2024-06-12 main B. Riley Securities Buy → Buy $9
2024-05-15 reit HC Wainwright & Co. Buy → Buy $21
News
RSS: Latest PDSB news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-02-28 FREITAG GREGORY GENE Director — 15,060 $1.33 $20,030
2025-02-28 GLOVER STEPHEN C Director — 15,061 $1.33 $20,031
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
31.54
-13.15%
36.32
-15.62%
43.05
+3.29%
41.67
Research And Development
19.03
-15.69%
22.57
-18.72%
27.76
-5.67%
29.43
Selling General And Administration
12.52
-9.00%
13.76
-9.99%
15.28
+24.84%
12.24
General And Administrative Expense
12.52
-9.00%
13.76
-9.99%
15.28
+24.84%
12.24
Other Gand A
12.52
-9.00%
13.76
-9.99%
15.28
+24.84%
12.24
Total Expenses
31.54
-13.15%
36.32
-15.62%
43.05
+3.29%
41.67
Operating Income
-31.54
+13.15%
-36.32
+15.62%
-43.05
-3.29%
-41.67
Total Operating Income As Reported
-31.54
+13.15%
-36.32
+15.62%
-43.05
-3.29%
-41.67
EBITDA
-30.30
+10.30%
-33.79
+15.80%
-40.12
+1.50%
-40.74
Normalized EBITDA
-30.30
+10.30%
-33.79
+15.80%
-40.12
+1.50%
-40.74
Reconciled Depreciation
0.02
+3.43%
0.02
+21.62%
0.02
+20084.88%
0.00
EBIT
-30.33
+10.29%
-33.81
+15.78%
-40.14
+1.46%
-40.74
Net Income
-34.50
+8.28%
-37.61
+12.42%
-42.94
-5.11%
-40.85
Pretax Income
-35.67
+7.31%
-38.48
+13.23%
-44.35
-5.46%
-42.05
Net Non Operating Interest Income Expense
-4.12
-90.95%
-2.16
-65.65%
-1.30
-241.69%
-0.38
Interest Expense Non Operating
5.34
+14.24%
4.67
+11.11%
4.21
+219.47%
1.32
Net Interest Income
-4.12
-90.95%
-2.16
-65.65%
-1.30
-241.69%
-0.38
Interest Expense
5.34
+14.24%
4.67
+11.11%
4.21
+219.47%
1.32
Interest Income Non Operating
1.22
-51.60%
2.51
-13.37%
2.90
+210.42%
0.94
Interest Income
1.22
-51.60%
2.51
-13.37%
2.90
+210.42%
0.94
Tax Provision
-1.17
-34.59%
-0.87
+38.18%
-1.41
-17.28%
-1.20
Tax Rate For Calcs
0.00
+50.52%
0.00
-29.41%
0.00
+10.34%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-34.50
+8.28%
-37.61
+12.42%
-42.94
-5.11%
-40.85
Net Income From Continuing Operation Net Minority Interest
-34.50
+8.28%
-37.61
+12.42%
-42.94
-5.11%
-40.85
Net Income From Continuing And Discontinued Operation
-34.50
+8.28%
-37.61
+12.42%
-42.94
-5.11%
-40.85
Net Income Continuous Operations
-34.50
+8.28%
-37.61
+12.42%
-42.94
-5.11%
-40.85
Normalized Income
-34.50
+8.28%
-37.61
+12.42%
-42.94
-5.11%
-40.85
Net Income Common Stockholders
-34.50
+8.28%
-37.61
+12.42%
-42.94
-5.11%
-40.85
Diluted EPS
-0.74
+28.16%
-1.03
+25.90%
-1.39
+2.80%
-1.43
Basic EPS
-0.74
+28.16%
-1.03
+25.90%
-1.39
+2.80%
-1.43
Basic Average Shares
46.38
+27.25%
36.45
+17.77%
30.95
+8.23%
28.60
Diluted Average Shares
46.38
+27.25%
36.45
+17.77%
30.95
+8.23%
28.60
Diluted NI Availto Com Stockholders
-34.50
+8.28%
-37.61
+12.42%
-42.94
-5.11%
-40.85
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
30.49
-32.77%
45.36
-23.63%
59.39
-22.88%
77.01
Current Assets
28.25
-37.29%
45.05
-23.71%
59.06
-22.78%
76.48
Cash Cash Equivalents And Short Term Investments
26.71
-35.93%
41.69
-26.29%
56.56
-23.38%
73.82
Cash And Cash Equivalents
26.71
-35.93%
41.69
-26.29%
56.56
-23.38%
73.82
Prepaid Assets
—
—
—
—
Other Current Assets
1.54
-54.17%
3.36
+34.89%
2.49
-6.23%
2.66
Total Non Current Assets
2.24
+636.32%
0.30
-9.19%
0.34
-36.50%
0.53
Net PPE
0.24
-19.89%
0.30
-9.19%
0.34
-36.50%
0.53
Gross PPE
0.42
-8.44%
0.46
-2.07%
0.47
-27.24%
0.64
Accumulated Depreciation
-0.18
-14.19%
-0.15
-15.90%
-0.13
-15.04%
-0.12
Properties
—
—
0.00
0.00
Buildings And Improvements
—
—
0.00
-100.00%
0.15
Machinery Furniture Equipment
0.03
+0.00%
0.03
+0.00%
0.03
+0.00%
0.03
Other Properties
0.39
-9.00%
0.43
-2.20%
0.44
-4.88%
0.46
Non Current Prepaid Assets
2.00
0.00
—
—
Total Liabilities Net Minority Interest
21.24
-19.40%
26.35
-20.76%
33.26
+0.77%
33.01
Current Liabilities
9.48
-44.50%
17.09
+25.36%
13.63
+38.78%
9.82
Payables And Accrued Expenses
4.04
+4.72%
3.86
-52.42%
8.12
+5.49%
7.70
Payables
3.57
+112.15%
1.68
-75.87%
6.98
+472.70%
1.22
Accounts Payable
3.57
+112.15%
1.68
-75.87%
6.98
+472.70%
1.22
Current Accrued Expenses
0.47
-78.40%
2.18
+91.88%
1.14
-82.47%
6.48
Pensionand Other Post Retirement Benefit Plans Current
0.27
-59.04%
0.66
-48.56%
1.29
-29.81%
1.84
Current Debt And Capital Lease Obligation
5.17
-58.87%
12.56
+197.48%
4.22
+1365.92%
0.29
Current Debt
5.13
-58.96%
12.50
+200.00%
4.17
—
Other Current Borrowings
5.13
-58.96%
12.50
+200.00%
4.17
—
Current Capital Lease Obligation
0.04
-40.83%
0.06
+9.54%
0.06
-80.63%
0.29
Total Non Current Liabilities Net Minority Interest
11.76
+26.90%
9.27
-52.79%
19.63
-15.34%
23.18
Long Term Debt And Capital Lease Obligation
11.76
+26.90%
9.27
-52.79%
19.63
-15.34%
23.18
Long Term Debt
11.73
+27.47%
9.20
-52.81%
19.51
-15.27%
23.02
Long Term Capital Lease Obligation
0.03
-58.47%
0.06
-49.70%
0.12
-25.02%
0.16
Stockholders Equity
9.25
-51.32%
19.00
-27.27%
26.13
-40.61%
44.00
Common Stock Equity
9.25
-51.32%
19.00
-27.27%
26.13
-40.61%
44.00
Capital Stock
0.02
+44.47%
0.01
+14.79%
0.01
+9.69%
0.01
Common Stock
0.02
+44.47%
0.01
+14.79%
0.01
+9.69%
0.01
Share Issued
54.88
+44.46%
37.99
+14.78%
33.09
+9.69%
30.17
Ordinary Shares Number
54.88
+44.46%
37.99
+14.78%
33.09
+9.69%
30.17
Additional Paid In Capital
225.84
+12.30%
201.10
+17.87%
170.62
+17.22%
145.55
Retained Earnings
-216.61
-18.94%
-182.11
-26.03%
-144.50
-42.28%
-101.56
Total Equity Gross Minority Interest
9.25
-51.32%
19.00
-27.27%
26.13
-40.61%
44.00
Total Capitalization
20.99
-25.61%
28.21
-38.19%
45.64
-31.91%
67.02
Working Capital
18.77
-32.88%
27.97
-38.43%
45.43
-31.85%
66.66
Invested Capital
26.12
-35.85%
40.71
-18.26%
49.80
-25.69%
67.02
Total Debt
16.93
-22.46%
21.83
-8.49%
23.85
+1.61%
23.47
Capital Lease Obligations
0.06
-49.70%
0.12
-31.21%
0.18
-60.45%
0.45
Net Tangible Assets
9.25
-51.32%
19.00
-27.27%
26.13
-40.61%
44.00
Tangible Book Value
9.25
-51.32%
19.00
-27.27%
26.13
-40.61%
44.00
Interest Payable
0.00
-100.00%
0.25
-17.75%
0.31
+9.41%
0.28
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-27.75
+20.78%
-35.03
-4.14%
-33.64
-30.83%
-25.71
Cash Flow From Continuing Operating Activities
-27.75
+20.78%
-35.03
-4.14%
-33.64
-30.83%
-25.71
Net Income From Continuing Operations
-34.50
+8.28%
-37.61
+12.42%
-42.94
-5.11%
-40.85
Depreciation Amortization Depletion
0.02
+3.43%
0.02
+21.62%
0.02
+20084.88%
0.00
Depreciation
0.02
+3.43%
0.02
+21.62%
0.02
+20084.88%
0.00
Depreciation And Amortization
0.02
+3.43%
0.02
+21.62%
0.02
+20084.88%
0.00
Other Non Cash Items
1.89
+29.29%
1.46
-21.94%
1.87
-65.77%
5.47
Stock Based Compensation
4.11
-40.03%
6.85
-10.06%
7.61
+46.54%
5.20
Operating Gains Losses
1.11
—
—
—
Change In Working Capital
-0.38
+93.34%
-5.75
-2786.31%
-0.20
-104.45%
4.47
Change In Prepaid Assets
-0.17
+80.06%
-0.87
-625.31%
0.17
+115.59%
-1.06
Change In Payables And Accrued Expense
-0.21
+95.71%
-4.88
-3790.24%
-0.13
-102.08%
6.04
Change In Accrued Expense
-2.10
-603.93%
0.42
+107.07%
-5.89
-196.13%
6.13
Change In Payable
1.89
+135.67%
-5.30
-191.92%
5.76
+6495.69%
-0.09
Change In Account Payable
1.89
+135.67%
-5.30
-191.92%
5.76
+6495.69%
-0.09
Change In Other Current Assets
—
—
0.00
+100.00%
-0.42
Change In Other Current Liabilities
0.00
0.00
+100.00%
-0.24
-222.03%
-0.07
Investing Cash Flow
0.00
+100.00%
-0.03
0.00
—
Cash Flow From Continuing Investing Activities
0.00
+100.00%
-0.03
0.00
—
Net PPE Purchase And Sale
0.00
+100.00%
-0.03
0.00
—
Purchase Of PPE
0.00
+100.00%
-0.03
0.00
—
Capital Expenditure
—
-0.03
—
—
Financing Cash Flow
12.77
-36.72%
20.19
+23.28%
16.38
-52.24%
34.29
Cash Flow From Continuing Financing Activities
12.77
-36.72%
20.19
+23.28%
16.38
-52.24%
34.29
Net Issuance Payments Of Debt
-7.56
-137.77%
-3.18
-5263.90%
-0.06
-100.24%
25.00
Issuance Of Debt
18.16
0.00
0.00
-100.00%
25.00
Repayment Of Debt
-25.73
-708.85%
-3.18
-5263.90%
-0.06
0.00
Long Term Debt Issuance
18.16
0.00
0.00
-100.00%
25.00
Long Term Debt Payments
-25.73
-708.85%
-3.18
-5263.90%
-0.06
0.00
Net Long Term Debt Issuance
-7.56
-137.77%
-3.18
-5263.90%
-0.06
-100.24%
25.00
Net Common Stock Issuance
13.98
-38.11%
22.60
+40.11%
16.13
+63.62%
9.86
Proceeds From Stock Option Exercised
6.35
+720.83%
0.77
+150.56%
0.31
+104.04%
0.15
Net Other Financing Charges
—
—
—
-0.72
Changes In Cash
-14.98
-0.72%
-14.87
+13.84%
-17.26
-301.22%
8.58
Beginning Cash Position
41.69
-26.29%
56.56
-23.38%
73.82
+13.15%
65.24
End Cash Position
26.71
-35.93%
41.69
-26.29%
56.56
-23.38%
73.82
Free Cash Flow
-27.75
+20.84%
-35.06
-4.23%
-33.64
-30.83%
-25.71
Interest Paid Supplemental Data
2.92
-17.86%
3.56
+0.61%
3.54
+314.81%
0.85
Common Stock Issuance
13.98
-38.11%
22.60
+40.11%
16.13
+63.62%
9.86
Issuance Of Capital Stock
13.98
-38.11%
22.60
+40.11%
16.13
+63.62%
9.86
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category